The contribution of spasticity to the movement disorder of cerebral palsy using pathway analysis: Does spasticity matter?

Developmental Medicine and Child Neurology

Volumn 53, Issue 1, 2011, Pages 7-9

  Lin, Jean Pierre ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; TETRABENAZINE;

BRAIN DEPTH STIMULATION; CEREBRAL PALSY; DEMOGRAPHY; DYSTONIA; ELECTROMYOGRAM; HUMAN; HYPERKINESIA; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NOTE; PATHOPHYSIOLOGY; PES EQUINUS; PHENOTYPE; PRIORITY JOURNAL; SPASTICITY;

CEREBRAL PALSY; HUMANS; MODELS, BIOLOGICAL; MOVEMENT DISORDERS; MUSCLE SPASTICITY;

EID: 78650053642     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2010.03843.x     Document Type: Note

References (11)

1. Kim WH, Park EY. Causal relationship between spasticity, strength, gross motor function, and functional outcome in children with cerebral palsy: a path analysis. Dev Med Child Neurol 2011; 53: 68-73. DOI: .
2. Malhotra S, Pandayan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil 2009; 23: 651-8.
3. Lance JW. Pathophysiology of spasticity and clinical experience with baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: Disordered Motor Control. Chicago, IL: Year Book Medical Publishers, 1980: 185-204.
4. Lin JP, Brown JK. Peripheral and central mechanisms of hindfoot equinus in childhood hemiplegia. Dev Med Child Neurol 1992; 34: 949-65.
5. Brown JK. Science and spasticity. Dev Med Child Neurol 1993; 35: 471-2.
6. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Task force on childhood motor disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111: e89-97.
7. Gainsborough M, Surman G, Maestri G, Colver A, Cans C; on behalf of the Surveillance of Cerebral Palsy in Europe collaborative group. Validity and reliability of the guidelines of the Surveillance of Cerebral Palsy in Europe for the classification of cerebral palsy. Dev Med Child Neurol 2008; 50: 828-31.
8. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1691-8.
9. Health: Cerebral Palsy Question for Short Debate House of Lords Grand Committees 4 November 2009, Volume No. 714, Part No. 129.
10. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25: 1538-49.
11. Lin J-P. The assessment and management of hypertonus in cerebral palsy: a physiological atlas (road map). In: Scrutton D, Damiano D, Mayston M, editors. Management of the Motor Disorders of Children with Cerebral Palsy. Clinics in Developmental Medicine No. 161.. London: Mac Keith Press, 2004: 85-104.